Mobile Health for Breast Cancer
Trial Summary
What is the purpose of this trial?
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it focuses on patients who are taking CDK4/6 inhibitors, so you should continue taking these as prescribed.
What data supports the effectiveness of the treatment Patient Navigation, Patient Navigation Services, Care Coordination, Healthcare Navigation for breast cancer?
Research shows that patient navigation can improve breast cancer care, especially for disadvantaged women, by helping them follow up on abnormal mammograms. Additionally, using patient navigators has been shown to improve the quality of breast cancer care, increasing adherence to care standards from 69% to 86%.12345
Is patient navigation safe for humans?
How is the treatment Patient Navigation unique for breast cancer patients?
Patient Navigation is unique because it focuses on guiding breast cancer patients through the healthcare system, improving care coordination and accessibility, especially for underserved populations. Unlike traditional treatments that directly target cancer cells, this approach uses mobile health (mHealth) apps to support patients and caregivers, ensuring timely and patient-centered care.49101112
Research Team
Gelareh Sadigh
Principal Investigator
ECOG-ACRIN Cancer Research Group
Eligibility Criteria
This trial is for metastatic breast cancer patients taking CDK4/6 inhibitors, fluent in English or Spanish, and healthcare providers involved with such patients. Patients must have started treatment within 30 days before joining or plan to start soon after. Providers need experience with a patient on CONCURxP who had less than 85% adherence.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the WiseBag medication dispenser and receive either enhanced usual care or the CONCURxP platform over 12 months
Follow-up
Participants are monitored for adherence, symptom burden, and quality of life after treatment
Treatment Details
Interventions
- Patient Navigation (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
ECOG-ACRIN Cancer Research Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator